secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009044
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology FY2022 net loss $120.7M; CFO promoted to CFO & COO
-----------------------------------------------------------------

- Net loss $120.7M ($3.65/share) vs $76.0M ($8.95) in 2021; R&D spend rose to $86.1M from $51.0M.
- Cash $180.7M with no debt as of Dec 31, 2022; runway into 1H 2025.
- Two Phase 1 trials for PYX-201 and PYX-106 initiated; preliminary data expected late 2023 to early 2024.
- CFO Pam Connealy promoted to additional role of COO effective March 22, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/pyxs-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer